Zevra Therapeutics Inc ZVRA

Healthcare

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

NDAQ:ZVRA - Post by User

Zevra Therapeutics Inc > Support?

<< Previous

Bullboard Posts

Next >>

Comment by Iseneschalon Feb 04, 2021 1:46pm

171 Views

Post# 32471918

RE:RE:RE:RE:RE:RE:Support?

Bobby90 wrote: If GPC buys them out then we can expect a share price of $30 minimum. New River Pharmaceuticals (Vyvanse) got bought out before approval for $2.6 billion.

Sounds good......in the mean time..... I just take profits when they stare me in the face.

Good luck to you!

Cheers

ps: I have no position now

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute